Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Sep 9

PMID 36078885

Authors

Minhui Wang

Ziqian Wang

Shangzhu Zhang

Yang Wu

Li Zhang

Jiuliang Zhao

Qian Wang

Xinping Tian

Mengtao Li

Xiaofeng Zeng

Affiliations

Soon will be listed here.

Abstract

Neuropsychiatric systemic lupus erythematosus (NPSLE) has a broad spectrum of subtypes with diverse severities and prognoses. Ischemic and inflammatory mechanisms, including autoantibodies and cytokine-mediated pathological processes, are key components of the pathogenesis of NPSLE. Additional brain-intrinsic elements (such as the brain barrier and resident microglia) are also important facilitators of NPSLE. An improving understanding of NPSLE may provide further options for managing this disease. The attenuation of neuropsychiatric disease in mouse models demonstrates the potential for novel targeted therapies. Conventional therapeutic algorithms include symptomatic, anti-thrombotic, and immunosuppressive agents that are only supported by observational cohort studies, therefore performing controlled clinical trials to guide further management is essential and urgent. In this review, we aimed to present the latest pathogenetic mechanisms of NPSLE and discuss the progress in its management.

Citing Articles

Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas.

Justiz-Vaillant A, Gopaul D, Soodeen S, Unakal C, Thompson R, Pooransingh S Microorganisms. 2024; 12(8).

PMID: 39203514 PMC: 11357253. DOI: 10.3390/microorganisms12081672.

A child with recurrent headache, fever and diffuse meningeal enhancement on MRI.

Khatua P, Bathia J, De H, Pal P Clin Rheumatol. 2024; 43(10):3249-3252.

PMID: 39127821 DOI: 10.1007/s10067-024-07030-2.

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.

Justiz-Vaillant A, Gopaul D, Soodeen S, Arozarena-Fundora R, Barbosa O, Unakal C Molecules. 2024; 29(4).

PMID: 38398500 PMC: 10892692. DOI: 10.3390/molecules29040747.

Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus.

Lee J, Broome S, Jansen M, Mandwie M, Logan G, Marzagalli R Int J Mol Sci. 2023; 24(13).

PMID: 37446298 PMC: 10342033. DOI: 10.3390/ijms241311118.

A case report: Catatonic symptoms secondary to systemic lupus erythematosus with multiple infections: neuropsychiatric or "mimickers?".

Lv L, Lin Y, Zhang Y, Xiao W, Li M, Zhao L Medicine (Baltimore). 2023; 102(23):e33746.

PMID: 37335678 PMC: 10256366. DOI: 10.1097/MD.0000000000033746.

References

Jongstra-Bilen J, Cano A, Hasija M, Xiao H, Smith C, Cybulsky M . Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol. 2008; 181(1):288-98. DOI: 10.4049/jimmunol.181.1.288. View

Magro-Checa C, Schaarenburg R, Beaart H, Huizinga T, Steup-Beekman G, Trouw L . Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2016; 25(8):878-88. DOI: 10.1177/0961203316643170. View

Vadgama T, Smith A, Bertolaccini M . Treatment in thrombotic antiphospholipid syndrome: a review. Lupus. 2019; 28(10):1181-1188. DOI: 10.1177/0961203319864163. View

Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimaki T, Peltola J . Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum. 2004; 50(3):858-65. DOI: 10.1002/art.20045. View

Jacob A, Weinshenker B, Violich I, McLinskey N, Krupp L, Fox R . Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65(11):1443-8. DOI: 10.1001/archneur.65.11.noc80069. View

Bortoluzzi A, Piga M, Silvagni E, Chessa E, Mathieu A, Govoni M . Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. Lupus. 2019; 28(4):465-474. DOI: 10.1177/0961203319828499. View

Furie R, Khamashta M, Merrill J, Werth V, Kalunian K, Brohawn P . Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2):376-386. PMC: 5299497. DOI: 10.1002/art.39962. View

Arinuma Y, Kikuchi H, Hirohata S . Anti-ribosomal P protein antibodies influence mortality of patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematous involving a severe form of the disease. Mod Rheumatol. 2018; 29(4):612-618. DOI: 10.1080/14397595.2018.1508801. View

Klein-Gitelman M, Brunner H . The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents. Curr Rheumatol Rep. 2009; 11(3):212-7. DOI: 10.1007/s11926-009-0029-x. View

10.

Niego B, Lee N, Larsson P, De Silva T, Au A, McCutcheon F . Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin. PLoS One. 2017; 12(5):e0177332. PMC: 5433693. DOI: 10.1371/journal.pone.0177332. View

11.

Tumani H, Huss A, Bachhuber F . The cerebrospinal fluid and barriers - anatomic and physiologic considerations. Handb Clin Neurol. 2017; 146:21-32. DOI: 10.1016/B978-0-12-804279-3.00002-2. View

12.

Husebye E, Sthoeger Z, Dayan M, Zinger H, Elbirt D, Levite M . Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 64(8):1210-3. PMC: 1755620. DOI: 10.1136/ard.2004.029280. View

13.

Wang J, Zhao Y, Zhang J, Lei H . Anti-N-Methyl-D-Aspartic Acid Receptor 2 (Anti-NR2) Antibody in Neuropsychiatric Lupus Serum Damages the Blood-Brain Barrier and Enters the Brain. Med Sci Monit. 2019; 25:532-539. PMC: 6346811. DOI: 10.12659/MSM.912389. View

14.

Gaber W, Ezzat Y, El Fayoumy N, Helmy H, Mohey A . Detection of asymptomatic cranial neuropathies in patients with systemic lupus erythematosus and their relation to antiribosomal P antibody levels and disease activity. Clin Rheumatol. 2014; 33(10):1459-66. DOI: 10.1007/s10067-014-2679-y. View

15.

Mok C . The Dawn of a New Era of Therapies in Systemic Lupus Erythematosus. Rheumatol Immunol Res. 2022; 1(1):31-37. PMC: 9524766. DOI: 10.2478/rir-2020-0005. View

16.

Chi O, Hunter C, Liu X, Weiss H . Effects of exogenous excitatory amino acid neurotransmitters on blood-brain barrier disruption in focal cerebral ischemia. Neurochem Res. 2009; 34(7):1249-54. DOI: 10.1007/s11064-008-9902-7. View

17.

Ben Salem C . The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368(24):2334. DOI: 10.1056/NEJMc1304515. View

18.

Matus S, Burgos P, Bravo-Zehnder M, Kraft R, Porras O, Farias P . Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med. 2007; 204(13):3221-34. PMC: 2150977. DOI: 10.1084/jem.20071285. View

19.

Meroni P, Raschi E, Testoni C, Tincani A, BALESTRIERI G, Molteni R . Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2002; 44(12):2870-8. DOI: 10.1002/1529-0131(200112)44:12<2870::aid-art475>3.0.co;2-y. View

20.

Mok C, Lau C, Wong R . Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med. 2003; 115(1):59-62. DOI: 10.1016/s0002-9343(03)00135-9. View